TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT05877300: Safety and Feasibility Study of the CELLSPAN Esophageal Implant (CEI) in Patients Requiring Short Segment Esophageal Replacement

Sponsor: Harvard Apparatus Regenerative Technology, Inc. · Phase: PHASE1 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 20 pts

Competing Trials Overlap

3 Active Trials

Excess Burn Exposure

$3,883,072

Rescue Site Savings

+$2,573,664

Unlock Full NCT05877300 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT05877300 Rescue Dossier →